What Happened
The California Supreme Court heard oral argument on May 6, 2026 in Gilead Tenofovir Cases, S283862, a coordinated mass action in which approximately 24,000 plaintiffs allege Gilead Sciences negligently delayed bringing tenofovir alafenamide (TAF) to market while continuing to sell the older HIV/HBV antiviral tenofovir disoproxil fumarate (TDF). The case is now under submission. Under the California Constitution’s 90-day rule, a written decision is required on or before approximately August 4, 2026.
The Issue Presented (per the Supreme Court)
The Court’s official issue statement, as published in its Issues Pending compilation, frames the question this way:
“Does a drug manufacturer have a duty of reasonable care to users of a drug it is currently selling, which is not alleged to be defective, when making decisions about the commercialization of an allegedly safer, and at least equally effective, alternative drug?”
Context
Plaintiffs do not contend that TDF itself is defective. Their theory is that Gilead, having developed TAF and concluded internally that it had a more favorable safety profile (particularly for bone density and renal function), made a business decision to delay TAF’s commercial launch in order to preserve revenue from TDF before its patent-protected exclusivity expired. The First District Court of Appeal allowed a negligence claim premised on that delay to proceed, concluding that a manufacturer’s duty of reasonable care can in some circumstances reach beyond the duty not to market a defective product. Defense observers have labeled the theory a “duty to innovate” — a framing not yet adopted by the courts.
The case has drawn an unusually heavy amicus presence. Filings opposing the lower-court rule include trade associations, several dozen manufacturers from outside the pharmaceutical industry (medical devices, automobiles, consumer goods), and certain patient-advocacy groups including the HIV and Hepatitis Policy Institute and Partnership to Fight Chronic Disease. Filings supporting the lower-court rule include the American Association for Justice, Consumer Attorneys of California, Justice Catalyst, and a group of public-health academics. Trade-press reports of the oral argument describe the justices as pressing both sides on workability — how a jury would assess the “reasonableness” of a development-and-launch timeline absent a defect, and whether such a rule is better suited to legislative drafting than common-law adoption.
What’s at Stake
- For pharmaceutical and life-sciences companies: Whether California recognizes a tort duty tied to the speed of developing or releasing safer successor products, even in the absence of a defect in the currently marketed product.
- For other regulated industries: The reasoning, if affirmed in broad terms, could be invoked by plaintiffs in any product line where a manufacturer has a known-safer successor on the shelf — automotive, medical devices, consumer electronics, agricultural chemicals. The cross-industry amicus list reflects that concern.
- For litigation strategy: Whether plaintiffs can plead around the traditional defect / failure-to-warn framework by reframing development-timing decisions as negligent commercialization.
- For the underlying coordinated proceeding: A reversal would substantially narrow the surviving claims; an affirmance would clear the path toward bellwether trials in the JCCP before Judge Andrew Y.S. Cheng in San Francisco.
What’s Next
- Decision deadline: On or before approximately August 4, 2026 (90 days from submission). The Court occasionally orders supplemental briefing, which resets submission; no such order has been reported in this case as of publication.
- Underlying coordinated proceeding (JCCP CJC19005043): Held in abeyance on the issues presented for review. Trial-court proceedings on remaining claims may resume promptly after the opinion issues.
- Related federal litigation: Federal TDF cases proceeding under different state-law regimes are not bound by the California Supreme Court’s eventual holding, but the reasoning will be widely cited.
Notes
This post describes a pending matter; no California Supreme Court decision has issued. Material is drawn from the California Supreme Court’s own public Issues Pending compilation (primary source for case caption, docket number, lower-court citation, and the issue statement) and from trade-press coverage of the oral argument and amicus briefing. Characterizations of the justices’ reactions at oral argument and of the parties’ strategic posture are sourced to that trade-press coverage and have not been verified against an oral-argument transcript or recording. The approximately 24,000 plaintiff count is a widely repeated figure from trade-press and party filings; the exact number on the coordinated docket may vary.